David A. Zilberberg

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,300,000 shares of its common stock. The common stock is listed on the…

Davis Polk advised the lead book-running managers in connection with the initial U.S. public offering of 6,000,000 common shares of TFI International, Inc. In addition, the underwriters…

Davis Polk is advising an ad hoc group (the “Ad Hoc Group”) of prepetition secured term lenders and postpetition DIP term lenders in connection with American Commercial Lines Inc.’s …

Davis Polk is advising Universal Scientific Industrial (Shanghai) Co., Ltd. on its acquisition of Asteelflash. Under the terms of the transaction agreement, USI will acquire 100% of the…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 46,000,000 shares of common stock of Plug Power Inc. for…

Davis Polk advised the underwriters in connection with the SEC-registered notes offering by Las Vegas Sands Corp. of $500 million of its 2.900% senior notes due 2025. Las Vegas Sands…

Davis Polk advised the initial purchasers in connection with an unregistered offering by AbbVie Inc. of $30 billion aggregate principal amount of senior notes, consisting of (i) $750…

Davis Polk advised the distribution agent on an SEC-registered at-the-market offering by Otter Tail Corporation of its common shares for up to an aggregate amount of $75 million. …

Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 4.250% senior notes…

Davis Polk advised the representatives and joint book-running managers of an SEC-registered offering by Black Hills Corporation of $400 million aggregate principal amount of its 3.050%…